Eli Lilly agreed this morning to buy AtaiBeckley, one of the market's few pure-play psychedelics companies. The terms: $6.75 a share in cash, about $2.8 billion, plus contingent payments of up to $2.50 a share if the pipeline hits development and regulatory milestones. All in, the deal is worth up to $3.8 billion.
The cash price is a 26% premium to Wednesday's close. ATAI is trading around $7.16, up more than 33% and above the cash offer, which means the market is already assigning real value to those milestone payments. The companies expect the deal to close in the third quarter.
What Lilly Is Actually Buying
The prize is BPL-003, a nasal spray built on mebufotenin, a synthetic version of 5-MeO-DMT. The compound is a fast-acting psychedelic best known for occurring naturally in toad venom. In a Phase 2b study, a single dose produced rapid and statistically significant reductions in depression symptoms that held for weeks, and the program is now headed into late-stage trials for treatment-resistant depression.
That last phrase is the market. Roughly a third of people treated for major depression do not respond to standard antidepressants. A treatment that works in one supervised dose, rather than a daily pill that takes weeks to kick in, would be a different product category entirely.
AtaiBeckley itself was formed last year when atai Life Sciences combined with Beckley Psytech. Within the past year this stock traded as low as $2.67 a share. Lilly is paying $6.75 in cash.
The Market Was Already Proven
Psychedelic medicine stopped being a fringe bet before this deal. Johnson & Johnson's Spravato, a nasal spray derived from ketamine, generated roughly $1.7 billion in sales last year treating the same condition, and some analysts project it reaches $3 billion by 2027. Spravato proved that regulators, insurers, and psychiatrists will support a supervised, clinic-administered psychiatric treatment at scale.
That is the template Lilly is buying into, and the price says how asymmetric the bet is. At a $1.1 trillion market cap and about 41 times trailing earnings, Lilly is spending roughly a quarter of one percent of its value for a late-stage shot at a proven market. For a company with a 35% net margin built on obesity drugs, this is an option, not a wager.
It also extends a pattern. Last week, Vertex agreed to pay $10 billion for Crinetics to buy growth beyond its core franchise. Big pharma is entering a patent-cliff decade with record cash, and clinical-stage biotech is where that cash is going.
The Read-Through Nobody Expected
The obvious sympathy trade did not work. Compass Pathways, whose psilocybin candidate is in late-stage trials for the same condition, is down around 3% on the day its field got validated by a $1.1 trillion buyer.
Two readings. The generous one: Compass had already more than tripled off its 52-week low of $3.83, and event-day profit-taking is normal. The colder one: Lilly looked at the psychedelics field, and at a Compass market cap of about $1.2 billion, and picked the other horse. Either way, Compass is now the most visible remaining pure-play target in a sector that just received its first multibillion-dollar big-pharma takeout.
Where This Goes
Watch three things. Whether a second major drugmaker responds with its own psychedelics deal, which would confirm this as a land grab rather than a one-off. Whether the deal closes cleanly in the third quarter. And Compass's late-stage psilocybin data, which is now the sector's next binary event and just gained a new class of potential acquirers watching it.
